Funding
Cerenis Therapeutics SA has received €2.5 million from OSEO, the state-backed company that provides financial support to French start-ups. The money will finance the clinical development of Cerenis’ portfolio of cardiovascular and metabolic diseases treatments.
The financing will support continued development of the company's CER-001 programme, enabling the company to apply for permission to conduct a clinical trial
“This new source of funding will support our efforts to advance [CER-001] through the Investigational New Drug approval process and onto clinical development,” said Jean-Louis Dasseux, president and CEO. “We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
